A major international study tracking more than 26,000 men over an extended period has found that very low testosterone levels are associated with an 18 percent higher risk of dying from cancer later in life. The research, which examined hormonal data alongside long-term health outcomes, suggests that testosterone deficiency may serve as an important early warning sign of future health risks. According to the findings, the elevated cancer mortality risk was particularly pronounced among men whose testosterone levels fell below 8.6 nanomoles per litre, a threshold researchers identified as a key marker of concern.
Surprisingly, the study found no clear link between testosterone itself and prostate cancer, challenging some long-held assumptions about the hormone's role in the disease. However, two other sex hormones did show an association with prostate cancer risk, though researchers did not specify which ones in the initial findings. The authors believe the results underscore the potential value of monitoring testosterone levels as part of routine health assessments, particularly for men with notably low readings. They cautioned that further research is needed to clarify the biological mechanisms behind the observed associations and to determine whether hormonal screening could meaningfully improve cancer outcomes through earlier intervention and targeted monitoring of at-risk populations.
Independent reporting synthesized from primary wires and global correspondents.